Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 0.67 |
| ▸ | CA1 | P00915 | 5/20 | 0.67 |
| ▸ | CA2 | P00918 | 5/20 | 0.67 |
| ▸ | CA7 | P43166 | 5/20 | 0.67 |
| ▸ | CA9 | Q16790 | 5/20 | 0.67 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.54 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.52 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | XDH | P47989 | 1/20 | 0.48 |
| ▸ | AR | P10275 | 2/20 | 0.48 |
| ▸ | EGFR | P00533 | 3/20 | 0.48 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.48 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29993089 | 0.85 | CA12 (0.67) | CA12CA1CA2CA7CA9 | |
| SCHEMBL256715 | 0.85 | CA12 (0.67) | CA12CA1CA2CA7CA9 | |
| SCHEMBL15326189 | 0.84 | CA12 (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL31585831 | 0.84 | CA12 (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1277539 | 0.82 | CA12 (0.44) | CA12CA1CA2CA7CA9 | |
| SCHEMBL12240241 | 0.81 | CA12 (0.43) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3895902 | 0.80 | CA12 (0.70) | CA12CA1CA2CA7CA9 | |
| SCHEMBL8067198 | 0.80 | CA12 (0.70) | CA12CA1CA2CA7CA9 | |
| SCHEMBL9600264 | 0.80 | EGFR (0.50) | CA12CA1CA2CA7CA9 | |
| Methyl 2,5-Dihydroxybenzoate SCHEMBL38890 | 0.80 | CA12 (1.00) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 219 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026102164-A1 | COMPOSITIONS AND METHODS OF USE THEREOF | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2026-05-15 | — | — | WO | disclosed |
| CN-122010913-A | Rhodamine-marked isoquinoline derivative and preparation method and application thereof | 淮阴师范学院 | 2026-05-12 | — | — | CN | disclosed |
| US-12577469-B2 | Compound, composition, cured product, optically anisotropic body, optical element, and light guide element | FUJIFILM CORPORATION (JP) | 2026-03-17 | — | — | US | disclosed |
| US-12576055-B2 | Disease detection and treatment based on trimethyl-lysine levels | THE CLEVELAND CLINIC FOUNDATION (US) | 2026-03-17 | — | — | US | disclosed |
| WO-2025059074-A1 | BICYCLIC COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV PHARMACEUTICALS, INC. (US) | 2025-03-20 | — | — | WO | disclosed |
| WO-2025013754-A1 | COMPOUND, COMPOSITION, CURED PRODUCT, OPTICALLY ANISOTROPIC BODY, OPTICAL ELEMENT, AND LIGHT GUIDE ELEMENT | 富士フイルム株式会社 | 2025-01-16 | — | — | WO | disclosed |
| WO-2024243289-A2 | GUT MICROBE DERIVED AROMATIC AMINO ACID METABOLITES FOR DETECTION AND TREATMENT OF DISEASE | THE CLEVELAND CLINIC FOUNDATION (US) | 2024-11-28 | — | — | WO | disclosed |
| WO-2024176696-A1 | RESIST COMPOSITION, RESIST PATTERN FORMATION METHOD, COMPOUND, AND POLYMER COMPOUND | 東京応化工業株式会社 | 2024-08-29 | — | — | WO | disclosed |
| US-12054660-B2 | Compound, composition, cured substance, optically anisotropic body, optical element, and light guide element | FUJIFILM CORPORATION (JP) | 2024-08-06 | — | — | US | disclosed |
| US-20240209263-A1 | LIQUID CRYSTAL COMPOUNDS | Rolic Technologies AG (CH) | 2024-06-27 | — | — | US | disclosed |
| US-5098930-A | Inhibitors of lipoxygenase for treatment of diseases mediated with leukotrienes | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-03-24 | — | — | US | disclosed |
| US-5089513-A | Antiinflammatory agents; antiallergens; asthma; side effect reduction | ICI PHARMA (FR) | 1992-02-18 | — | — | US | disclosed |
| US-5039511-A | Amyloidosis and alzheimer's disease diagnostic assay and reagents therefor | SALUTAR, INC. (US) | 1991-08-13 | — | — | US | disclosed |
| US-5015661-A | Lipoxygenase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 1991-05-14 | — | — | US | disclosed |
| US-5008099-A | Amyloidosis and Alzheimer's disease diagnostic assay and reagents therefor | SALUTAR, INC. (US) | 1991-04-16 | — | — | US | disclosed |
| US-4959391-A | LIPOXYGENASE INHIBITORS, LEUKOTRIENE DISEASES | GRUENENTHAL GMBH (DE) | 1990-09-25 | — | — | US | disclosed |
| EP-0375404-A2 | Heterocyclic derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-06-27 | — | — | EP | disclosed |
| US-4933156-A | Amyloidosis and Alzheimer's disease diagnostic assay and reagents therefor | SALUTAR, INC. (US) | 1990-06-12 | — | — | US | disclosed |
| EP-0287909-A1 | Amyloidosis and Alzheimer's disease diagnostic assay and reagents therefor | SALUTAR, INC. (US) | 1988-10-26 | — | — | EP | disclosed |
| US-4760087-A | 5-lipoxygenase inhibitor | GRUENENTHAL GMBH (DE) | 1988-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12054660-B2 | Compound, composition, cured substance, optically anisotropic body, optical element, and light guide element | SP1, C5, ZYX | CA12 339/4885CA1 132/4885CA2 1198/4885 |
| US-12576055-B2 | Disease detection and treatment based on trimethyl-lysine levels | BHMT, BHMT2, EHMT2 | CA12 1832/4885CA1 2402/4885CA2 1446/4885 |
| US-12577469-B2 | Compound, composition, cured product, optically anisotropic body, optical element, and light guide element | CRY2, SCO2, CRY1 | CA12 320/4885CA1 865/4885CA2 589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.